Opinion|Videos|March 27, 2024
Safety Profile Considerations for Enfortumab Vedotin Plus Pembrolizumab
A comprehensive discussion on treatment-related adverse events seen in patients receiving enfortumab vedotin and pembrolizumab.
Advertisement
Advertisement
Related to this article
The FDA granted fast track designation to SBE303, Samsung Bioepis’ investigational Nectin-4–targeting ADC, for advanced urothelial cancer following enfortumab vedotin.
UGN-103, a formulation of intravesical mitomycin as treatment for low-grade intermediate-risk non–muscle-invasive bladder cancer, will receive FDA review with a PDUFA date of June 14, 2027.
FDA expands nogapendekin alfa inbakicept plus BCG use to high-grade papillary-only BCG-unresponsive NMIBC, offering durable control and strong cystectomy-avoidance outcomes.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Alignment Reached on Phase 3 Design for RGT-61159 in ACC
2
FDA Grants Traditional Approval to Pembrolizumab in TMB-High Solid Tumors
3
Sofetabart Mipitecan Elicits Responses Across FRα Levels in Ovarian Cancer
4
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
5